Login   |  Users Online: 2190 Home Print this page Email this page Small font sizeDefault font sizeIncrease font size
Search Article 
  
Advanced search 
   Home | About us | Editorial board | Search | Ahead of print | Current issue | Archives | Submit article | Instructions | Subscribe | Contacts
CLINICAL RESEARCH
Year : 2012  |  Volume : 33  |  Issue : 1  |  Page : 38-43

Clinical evaluation of Rasayana compound as an adjuvant in the management of tuberculosis with anti-Koch's treatment


1 Ksharasutra Vaidya, Smt. Maniben Govt. Ayurvedic Hospital, Ahmedabad, India
2 Professor and Head, Department of Kaya Chikitsa, Institute for Post Graduate Teaching and Research in Ayurveda, Gujarat Ayurved University, India
3 Professor, and Head, Department of Pulmonary Medicine, G.G. Hospital, M.P. Shah Medical College, Jamnagar, India
4 Founder and Managing Director, Synchron Research Pvt. Ltd., Ahmedabad, Gujarat, India

Correspondence Address:
Purvi Vyas
Ksharasutra Vaidya, Smt. Maniben Govt. Ayurvedic Hospital, Ahmedabad, Gujarat
India
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/0974-8520.100307

Rights and Permissions

Tuberculosis (TB) continues to intimidate the human race since time immemorial not only due to its effects as a medical malady, but also by its impact as a social and economic tragedy. At the dawn of the new millennium, we are still mute witnesses to the silent yet efficient march of this sagacious disease, its myriad manifestations and above all its unequalled, vicious power. Through the millennia, TB never ever disappeared from the developing world. In 1991, the World Health Assembly (WHA) resolution recognized TB as a major global public health problem. The DOTS strategy was launched in 1994, and became the global recommended strategy for TB control since then. The present study deals with clinical evaluation of Rasayana drugs considering of Amalaki (Emblica officinalis Gaertn.), Guduchi (Tinospora cordifolia willd.), Ashwagandha (Withania somnifera L.) Dunal, Yastimadhu (Glycyrrhiza glabra Linn.), Pippali (Piper longum Linn.), Sariva (Hemidesmus indicus R.Br.), Kustha (Saussurea lappa Falc.), Haridra (Curcuma longa Linn.) and Kulinjan (Alpinia galangal Linn.) as an adjuvant therapy with anti-Koch's treatment. The results obtained revealed that Rasayana compound was found to decrease cough (83%), fever (93%), dyspnea (71.3%), hemoptysis (87%) and increase body weight (7.7%) with statistically highly significant (P<0.001).


[FULL TEXT] [PDF]*
Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)
 

 Article Access Statistics
    Viewed2832    
    Printed85    
    Emailed0    
    PDF Downloaded766    
    Comments [Add]    
    Cited by others 1    

Recommend this journal